TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00521183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochlor
Description: The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
Study: NCT04297592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg oral tablet, 4 times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg oral tablet, 2 times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefadroxil
Description: 500 mg oral tablet, 2 times daily for 7 days
Study: NCT02698293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: orally, 40 mg/kg 4-6 hours prior to light application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: orally, 40 mg/kg 4-6 hours prior to light application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: orally, 40 mg/kg 4-6 hours prior to light application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol)
Description: Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol)
Description: Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol)
Description: Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therpay
Description: Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therpay
Description: Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therpay
Description: Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter.
Study: NCT03101020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Visceral Manipulation
Description: Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care physiotherapy
Description: The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care physiotherapy
Description: The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Visceral Manipulation
Description: The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
Study: NCT03359746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: Medication for treatment of patient
Study: NCT03120611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercise
Description: Game developed by the Kinect, adapted to the lying position of participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise intradialysis
Description: Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
Study: NCT02933814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine
Description: Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
Study: NCT02329717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI 05204
Description: PBI 05204 daily dosing
Study: NCT00844311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: 150 iu/day of rFSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: 150 iu/day of rFSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: 150 iu/day of rFSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: 150 iu/day of rFSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: 50 iu/day of hCG from stimulation day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: 100 iu/day of hCG from stimulation day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: 150 iu/day of hCG from stimulation day 1
Study: NCT01072591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-578
Description: intravenous infusion, once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEDI-578
Description: Intravenous infusion, once
Study: NCT02049216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible tape
Description: Flexible, elasticised, adhesive athletic tape

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fixomull

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in both groups will be prescribed a home exercise program to complete.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Participants in both groups will be prescribed a home exercise program to complete.
Study: NCT04197440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 2mg/ml
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 1mg/ml
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 0.5 mg/ml
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with 1 SPT
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with 5 SPT
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with 25 SPT
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with inactivate cowhage spicules
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT01963234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seva
Description: Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
Study: NCT01192815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally or via gastronomy tube

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Optional ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Optional correlative studies
Study: NCT02287077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
Study: NCT03444584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous dose of placebo matched to MEDI0382.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaglifozin
Description: Oral dose of dapaglifozin 10 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapaglifozin
Description: Oral dose of dapaglifozin 10 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).
Study: NCT03211507

Intervention type: OTHER
Intervention: Computer-assisted telephone interview
Description: Occupational history

Intervention type: OTHER
Intervention: Computer-assisted telephone interview
Description: Occupational history

Intervention type: GENETIC
Intervention: Genetic analysis
Description: To include analysis of known susceptibility markers

Intervention type: GENETIC
Intervention: Genetic analysis
Description: To include analysis of known susceptibility markers
Study: NCT03350919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training in the blind field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
Study: NCT03698500

Intervention type: OTHER
Group type: OTHER
Intervention: Removal of blood
Description: 10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw
Study: NCT00476970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
Study: NCT03350919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training in the intact field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
Study: NCT01032928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory-Swallow Phase training
Description: Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
Study: NCT01850316

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
Study: NCT03173274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention
Description: Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingent Reinforcement for negative breath CO samples

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contingent Reinforcement
Description: Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value \[CM control\]
Study: NCT04301531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass testing using RDTs
Description: To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.

Intervention type: OTHER
Group type: OTHER
Intervention: Mass testing using RDTs
Description: To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment for all cases confirmed positive malaria cases with ACTs
Description: During each mass testing, all confirmed positive cases are treated in both arms.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment for all cases confirmed positive malaria cases with ACTs
Description: During each mass testing, all confirmed positive cases are treated in both arms.
Study: NCT01096940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet, BID dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet, BID dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Oral tablet, single dose
Study: NCT05563324

Intervention type: GENETIC
Intervention: DNA extraction and genotyping of candidate genetic polymorphisms

Intervention type: GENETIC
Intervention: DNA extraction and genotyping of candidate genetic polymorphisms

Intervention type: GENETIC
Intervention: DNA extraction and genotyping of candidate genetic polymorphisms

Intervention type: OTHER
Intervention: self-assessment questionnaires

Intervention type: OTHER
Intervention: self-assessment questionnaires
Study: NCT00911911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BIOPSY
Description: Biopsy at the moment of inclusion, before neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SURGERY
Description: Surgery after neoadjuvant chemotherapy
Study: NCT03146390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential oils
Description: all subjects will perform all interventions of all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol free essential oils
Description: all subjects will perform all interventions of all arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: all subjects will perform all interventions of all arms
Study: NCT01285518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 0.5 mg QD IV x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 1.5 mg QD IV x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 5 mg QD IV x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 15 mg QD IV x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 50 mg QD IV x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 100 mg QD IV x 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 200 mg QD IV x 1 day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, USP QD IVx 1 day
Study: NCT03713918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced lithium silicate endocrowns
Description: The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post retained reinforced lith silicate crn
Description: The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.